trending Market Intelligence /marketintelligence/en/news-insights/trending/oV9sZR6hhZUo_IlG_ukgxg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

TFF Pharmaceuticals approved for listing on Nasdaq Capital Market

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

TFF Pharmaceuticals approved for listing on Nasdaq Capital Market

TFF Pharmaceuticals Inc. 's common stock was approved for listing on the Nasdaq Capital Market and will begin trading under the TFFP symbol on Oct. 25.

The Austin, Texas-based biopharmaceutical company priced its IPO of 4.4 million common shares on the stock exchange at $5 per share. TFF also granted the underwriter a 45-day option to buy an additional 660,000 common stock at the same price.

Gross proceeds from the IPO are expected to be about $22 million.

The company plans to use net proceeds to advance the development of TFF Vori, an inhaled dry powder drug for the treatment of pulmonary diseases, and TFF Tac-Lac — an inhaled dry powder version of immunosuppressive drug Prograf. Proceeds will also be used for general working capital.

The offering is expected to close on Oct. 29.

National Securities Corp. is acting as the sole underwriter for the offering while The Liquid Venture Partners group at National Securities Corp. was responsible for sourcing and executing the IPO.